News

PD Neurotechnology® at MDS PAS Congress 2022

Published on: 03/08/2022

PD Neurotechnology® at MDS PAS Congress 2022
Partnerships and Growth
Member News

PD Neurotechnology® was present as an exhibitor and a bronze sponsor at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress, held on May 26-28, in Miami Florida, a successful event with more than 400 registrants from 22 countries.0693e3

The  4th Pan American Parkinson’s Disease and Movement Disorders Congress 2022 was a unique opportunity for the company to introduce PDMonitor® to movement disorders specialists from the Americas and officially launch its commercialization pre-sales efforts in the region.

PD Neurotechnology® also organized its first US Medical Advisory Board meeting (MAB), which helped steer the company’s strategy in the US and lay the foundation for the next round of investigator driven clinical studies to prove PDMonitor®’s usefulness in daily practice.

Nikos Moschos, Founder and Business Director of PD Neurotechnology® commented: “It was a pleasure to welcome our booth physicians and industry experts and to present to them how PDMonitor® is driving a paradigm shift in Parkinson’s disease management. The US market presents a major opportunity and we can’t wait to make PDMonitor® available to the market for the benefit of Parkinson’s patients. In this effort, the support of our highly talented and visionary Medical Advisory Board will be insurmountable.”

Discover more about PD Neurotechnology Ltd:

PD Neurotechnology Ltd. is an awarded, high-tech medical device company, founded in London, UK in 2015, certified with ISO 9001:2015, ISO 27001:2013, ISO 27701:2019 and ISO 13485:2016. Its first product, PDMonitor is a CE marked, Class IIa medical device, a digital, noninvasive, continuous monitoring system and management tool, used by patients with Parkinson’s Disease, which enables an accurate motor symptom evaluation, coupled with information on lifestyle and drug adherence. A web application offers the treating physician a comprehensive and objective view of the patient status and supports the assessment of the disease stage and prompt and optimal modification of the treatment. PDMonitor is currently marketed in 10 European countries, soon to be available in the US, post FDA clearance.

NEWS​

Related News

New Round Tables announced to drive progress on EHDS and health AI

3 Jul 2025

The European Accessibility Act Is Here. Are You Ready?

2 Jul 2025
Why inclusive design is no longer optional – and how Big Motive can help you lead the way.

DTH-Lab Director: The G7 must act now to address the digital health transformation

2 Jul 2025
As digital platforms increasingly shape health systems and information flows, the G7 must lead in setting global standards to ensure safety, equity an...

InnoHSupport Open Calls

1 Jul 2025
Welcome to the InnoHSupport Open Calls!

Transformative Health Instrument Call 2025

1 Jul 2025
Apply to the Transformative Health Instrument (THI) Call 2025 if you are a growing and innovative healthcare start-up working on solutions that have s...

Longitude Prize on ALS

1 Jul 2025
The £7.5 million (~$10 million) Longitude Prize on ALS incentivises the use of AI-based approaches to transform drug discovery for amyotrophic lateral...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *